Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma

Kairat Tabynov; Elmira Tailakova; Guliza Rakhmatullayeva; Turlan Bolatbekov; Yeow Hong Lim; Gleb Fomin; Meruert Babayeva; Rudolf Valenta; Kaissar Tabynov

doi:10.1038/s41541-025-01112-1

Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma

Kairat Tabynov, Elmira Tailakova, Guliza Rakhmatullayeva, Turlan Bolatbekov, Yeow Hong Lim, Gleb Fomin, Meruert Babayeva, Rudolf Valenta, Kaissar Tabynov

Scientific Working Group Allergology and Immunology

Research output: Journal article (peer-reviewed) › Journal article

Abstract

Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with Artemisia vulgaris pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG1/IgG2a, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy.

Original language	English
Article number	66
Pages (from-to)	66
Journal	npj Vaccines
Volume	10
Issue number	1
DOIs	https://doi.org/10.1038/s41541-025-01112-1
Publication status	Published - 02 Apr 2025

Access to Document

10.1038/s41541-025-01112-1

Cite this

@article{7484934285ed447a84f60057796b4bcf,

title = "Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma",

abstract = "Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with Artemisia vulgaris pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG1/IgG2a, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy.",

author = "Kairat Tabynov and Elmira Tailakova and Guliza Rakhmatullayeva and Turlan Bolatbekov and Lim, {Yeow Hong} and Gleb Fomin and Meruert Babayeva and Rudolf Valenta and Kaissar Tabynov",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = apr,

day = "2",

doi = "10.1038/s41541-025-01112-1",

language = "English",

volume = "10",

pages = "66",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma

AU - Tabynov, Kairat

AU - Tailakova, Elmira

AU - Rakhmatullayeva, Guliza

AU - Bolatbekov, Turlan

AU - Lim, Yeow Hong

AU - Fomin, Gleb

AU - Babayeva, Meruert

AU - Valenta, Rudolf

AU - Tabynov, Kaissar

PY - 2025/4/2

Y1 - 2025/4/2

N2 - Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with Artemisia vulgaris pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG1/IgG2a, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy.

AB - Mugwort-allergic patients frequently experience severe respiratory allergies due to sensitization to the major allergen Art v 1, with allergen-specific immunotherapy (ASIT) as the only causal treatment to halt disease progression. This study evaluated the effects of subcutaneous (SCIT) and sublingual (SLIT) ASIT with purified recombinant Art v 1 (rArt v 1) in a murine model of mugwort pollen of asthma. BALB/c mice were sensitized with Artemisia vulgaris pollen extract and treated with either rArt v 1-based SCIT adjuvanted with Montanide ISA-51, rArt v 1-based SLIT, an extract-based commercial SLIT vaccine, or PBS. Both rArt v 1-based SCIT and SLIT improved lung pathology and reduced airway reactivity following allergen challenge, with rArt v 1-based SCIT inducing Th1-polarized immune responses marked by increased IFN-γ production and rArt v 1-specific IgG1/IgG2a, while SLIT induced stronger mucosal IgA responses. These findings highlight the therapeutic potential of rArt v 1-based ASIT for mugwort allergy.

UR - http://www.scopus.com/inward/record.url?scp=105001716715&partnerID=8YFLogxK

U2 - 10.1038/s41541-025-01112-1

DO - 10.1038/s41541-025-01112-1

M3 - Journal article

C2 - 40175385

SN - 2059-0105

VL - 10

SP - 66

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 66

ER -

Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this